한글목차

세계의 유도만능줄기세포 시장은 2025년 15억 9,900만 달러로 추정되고, 2032년까지 33억 8,310만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 11.3%로 성장할 것으로 예측됩니다.

그림. 유도만능줄기세포 세계 시장 점유율(%), 2025년 지역별

유도만능줄기세포(iPSC)는 성체세포에서 직접 제작할 수 있는 다능성 줄기세포의 일종입니다. 유도만능줄기세포(iPSC)는 유전적으로 배아 줄기 세포와 같은 만능 상태로 재프로그램 된 성체 세포입니다. iPSC의 재생 특성은 세포 기반 치료법을 개발할 수있는 기회를 제공합니다.

시장 역학:

세계의 유도만능줄기세포 시장은 만성질환 증가, 장기이식 증가, 줄기세포를 이용한 신규 치료법 개발을 위한 바이오의약품 기업에 의한 연구개발(R&D) 투자 증가에 의해 견인되고 있습니다. 줄기세포의 분화에 있어서의 기술적 과제가 시장의 성장을 억제하고 있습니다. 한편, 표준적인 배양방법의 확립, 제노프리의 초기화법의 개발, 대규모 줄기세포 생산의 진전 등, 줄기세포 기술의 진보는 계속되고 있어 시장 관계자에게 유리한 성장 기회를 제공할 것으로 기대되고 있습니다.

본 조사의 주요 특징

• 본 보고서는 세계의 유도만능줄기세포 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 시장 규모 및 복합연간 성장률(CAGR)을 제공합니다.
• 또한 다양한 부문에서 잠재적인 수익 성장 기회를 밝혀 이 시장에 대한 매력적인 투자 제안의 매트릭스에 대해 설명하고 있습니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 주요 고찰도 제공합니다.
• 세계의 유도만능줄기세포 시장에 있어서의 주요 기업 프로파일을, 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 업적, 전략 등의 파라미터에 근거해 제공합니다.
• 이 보고서는 Takara Bio Inc., Thermo Fisher Scientific, Fujifilm Holdings Corporation, Astellas Pharma, Fate Therapeutics, Ncardia, ViaCyte, Cellular Dynamics International, Lonza, Blueprint Medicines 및 기타 주요 기업을 다룹니다.
• 본 보고서로부터의 인사이트는 마케팅 담당자나 기업의 경영진이, 장래의 제품 발매, 유형 업, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시하는 것을 가능하게 할 것입니다.
• 세계의 유도만능줄기세포 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해 관계자에 대응하고 있습니다.
• 이해관계자는 세계의 유도만능줄기세포 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 성장 촉진요인
  • 억제요인
  • 기회
• 주요 하이라이트
• 규제 시나리오
• 최근 동향
• 제품 출시/승인
• PEST 분석
• PORTER 분석
• 합병, 인수 및 제휴

제4장 세계의 유도만능줄기세포 시장-코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측의 분석
• 경제에 미치는 영향

제5장 세계의 유도만능줄기세포 시장, 세포원별, 2020-2032년

• 피부 유래 iPSC
• 혈액 유래 iPSC
• 소변 유래 iPSC
• 간세포 유래 iPSC
• 폐섬유아세포 유래 iPSC
• 기타(내피세포, 신경교세포, 지방 줄기세포 등)

제6장 세계의 유도만능줄기세포 시장, 용도별, 2020-2032년

• 배양과 유지
• 차별화
• 유전자 조작과 공학
• 특성 평가 및 검증
• 은행 및 보관
• 기타(리프로그래밍 키트, 해석 소프트웨어 등)

제7장 세계의 유도만능줄기세포 시장, 최종 사용자별, 2020-2032년

• 병원
• 진단센터
• 제약 및 바이오테크놀러지 기업
• 계약 연구 기관
• 기타(학술연구 기관 등)

제8장 세계의 유도만능줄기세포 시장, 지역별, 2020-2032년

• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동
• 아프리카

제9장 경쟁 구도

• 기업 프로파일
  • Takara Bio Inc.
  • Thermo Fisher Scientific
  • Fujifilm Holdings Corporation
  • Astellas Pharma
  • Fate Therapeutics
  • Ncardia
  • ViaCyte
  • Cellular Dynamics International
  • Lonza
  • Blueprint Medicines
  • Other Prominent Players

제10장 섹션

• 참고문헌
• 조사 방법
• 출판사에 대해

영문목차

Global Induced Pluripotent Stem Cells Market is estimated to be valued at USD 1,599.0 Mn in 2025 and is expected to reach USD 3,383.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 11.3% from 2025 to 2032.

Figure. Global Induced Pluripotent Stem Cells Market Share (%), By Region 2025

Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The discovery of induced pluripotent stem cells revolutionized the field of regenerative medicine as it provided an ethically superior alternative to embryonic stem cells. Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to an embryonic stem cell-like pluripotent state. iPSCs are used in regenerative medicine research to study mechanisms of disease and for drug discovery and toxicity screening. Regenerative properties of iPSCs provide opportunities for developing cell-based therapies. These cells are reprogrammed from their original differentiated adult cells through the introduction or overexpression of key transcription factors that enable them to regress to a state that resembles embryonic stem cells in terms of differentiation potential and expression of pluripotency markers. This technology holds tremendous promise for developing patient and disease specific stem cell models for drug discovery, toxicity screening, and regenerative therapies.

Market Dynamics:

Global induced pluripotent stem cells market is driven by rising prevalence of chronic diseases, increasing adoption of organ transplantation and growing research and development (R&D) investments by biopharmaceutical companies for developing novel stem cell-based therapies. However, high costs that are associated with iPSC research and clinical applications, technical challenges in cell reprogramming and stem cell differentiation are restraining wider market growth. Meanwhile, ongoing advancements in stem cell technologies including establishment of standard culture practices, development of xeno-free reprogramming methods and progress in large-scale stem cell production are expected to offer lucrative growth opportunities for market players.

Key features of the study:

• This report provides an in-depth analysis of the global induced pluripotent stem cells market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global induced pluripotent stem cells market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• The key companies covered as a part of this study include Takara Bio Inc., Thermo Fisher Scientific, Fujifilm Holdings Corporation, Astellas Pharma, Fate Therapeutics, Ncardia, ViaCyte, Cellular Dynamics International, Lonza, Blueprint Medicines, and Other Prominent Players.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global induced pluripotent stem cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global induced pluripotent stem cells market.

Detailed Segmentation:

• By Cell Source:
  • Skin derived iPSCs
  • Blood derived iPSCs
  • Urine Derived iPSCs
  • Hepatocytes derived iPSCs
  • Lung fibroblast derived iPSCs
  • Others (Endothelial cells, Glial Cells, Adipose stem cells etc.)
• By Application:
  • Culture & Maintenance
  • Differentiation
  • Genetic Manipulation & Engineering
  • Characterization & Validation
  • Banking & Storage
  • Others (Reprogramming kits, Analysis software etc.)
• By End User:
  • Hospitals
  • Diagnostics Centers
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Others (Academic & Research Institutes etc.)
• By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Takara Bio Inc.
  • Thermo Fisher Scientific
  • Fujifilm Holdings Corporation
  • Astellas Pharma
  • Fate Therapeutics
  • Ncardia
  • ViaCyte
  • Cellular Dynamics International
  • Lonza
  • Blueprint Medicines
  • Other Prominent Players

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Induced Pluripotent Stem Cells Market Snippet, By Cell Source
  • Global Induced Pluripotent Stem Cells Market Snippet, By Application
  • Global Induced Pluripotent Stem Cells Market Snippet, By End User
  • Global Induced Pluripotent Stem Cells Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Key Highlights
• Regulatory Scenario
• Recent Trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers, Acquisitions, and Collaborations

4. Global Induced Pluripotent Stem Cells Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Induced Pluripotent Stem Cells Market, By Cell Source, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Skin derived iPSCs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Blood derived iPSCs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Urine Derived iPSCs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Hepatocytes derived iPSCs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Lung fibroblast derived iPSCs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Endothelial cells, Glial Cells, Adipose stem cells etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Induced Pluripotent Stem Cells Market, By Application, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Culture & Maintenance
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Differentiation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Genetic Manipulation & Engineering
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Characterization & Validation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Banking & Storage
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Reprogramming kits, Analysis software etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Induced Pluripotent Stem Cells Market, By End User, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Diagnostics Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Pharmaceutical & Biotechnology Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Contract Research Organizations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Academic & Research Institutes etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. Global Induced Pluripotent Stem Cells Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Mn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Company Profile
  • Takara Bio Inc.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Thermo Fisher Scientific
  • Fujifilm Holdings Corporation
  • Astellas Pharma
  • Fate Therapeutics
  • Ncardia
  • ViaCyte
  • Cellular Dynamics International
  • Lonza
  • Blueprint Medicines
  • Other Prominent Players
• Analyst Views

10. Section

• References
• Research Methodology
• About us